Chemerin Is a Novel Adipocyte-Derived Factor Inducing Insulin Resistance in Primary Human Skeletal Muscle Cells by Sell, Henrike et al.
Chemerin Is a Novel Adipocyte-Derived Factor Inducing
Insulin Resistance in Primary Human Skeletal Muscle
Cells
Henrike Sell,
1 Jurga Laurencikiene,
2 Annika Taube,
1 Kristin Eckardt,
1 Andrea Cramer,
1
Angelika Horrighs,
1 Peter Arner,
2 and Ju ¨rgen Eckel
1
OBJECTIVE—Chemerin is an adipokine that affects adipogen-
esis and glucose homeostasis in adipocytes and increases with
BMI in humans. This study was aimed at investigating the
regulation of chemerin release and its effects on glucose metab-
olism in skeletal muscle cells.
RESEARCH DESIGN AND METHODS—Human skeletal mus-
cle cells were treated with chemerin to study insulin signaling,
glucose uptake, and activation of stress kinases. The release of
chemerin was analyzed from in vitro differentiated human adi-
pocytes and adipose tissue explants from 27 lean and 26 obese
patients.
RESULTS—Human adipocytes express chemerin and chemo-
kine-like receptor 1 (CMKLR1) differentiation dependently and
secrete chemerin (15 ng/ml from 10
6 cells). This process is
slightly but signiﬁcantly increased by tumor necrosis factor-
and markedly inhibited by 80% by peroxisome proliferator–
activated receptor- activation. Adipose tissue explants from
obese patients are characterized by signiﬁcantly higher chemerin
secretion compared with lean control subjects (21 and 8 ng from
10
7 cells, respectively). Chemerin release is correlated with BMI,
waist-to-hip ratio, and adipocyte volume. Furthermore, higher
chemerin release is associated with insulin resistance at the level
of lipogenesis and insulin-induced antilipolysis in adipocytes.
Chemerin induces insulin resistance in human skeletal muscle
cells at the level of insulin receptor substrate 1, Akt and glycogen
synthase kinase 3 phosphorylation, and glucose uptake. Further-
more, chemerin activates p38 mitogen-activated protein kinase,
nuclear factor-B, and extracellular signal–regulated kinase
(ERK)-1/2. Inhibition of ERK prevents chemerin-induced insulin
resistance, pointing to participation of this pathway in chemerin
action.
CONCLUSIONS—Adipocyte-derived secretion of chemerin
may be involved in the negative cross talk between adipose
tissue and skeletal muscle contributing to the negative relation-
ship between obesity and insulin sensitivity. Diabetes 58:
2731–2740, 2009
O
besity is one of the most serious health hazards,
especially in the Western world. Frequently,
obesity is accompanied by metabolic distur-
bances, such as insulin resistance, hyperglyce-
mia, dyslipidemia, hypertension, and other components of
the metabolic syndrome (1,2). Insulin resistance is a
hallmark of obesity, emerging early in the metabolic
syndrome, and is highly associated with increased visceral
adipose tissue mass. The concept of adipose tissue as a
major secretory and endocrine active organ producing a
variety of bioactive proteins that may regulate energy
metabolism and insulin sensitivity is now widely accepted
(3), and increased adipose tissue mass, especially in the
visceral compartment, is now described as one of the
major risk factors for the development of type 2 diabetes
(4–6). Adipocytes from obese subjects are characterized
by altered metabolic and endocrine function leading to an
increased secretion of proinﬂammatory adipokines, such
as tumor necrosis factor (TNF)-, interleukin (IL)-6, an-
giotensinogen, and resistin (7,8). It is likely that some of
these secreted molecules may be factors underlying the
association of increased body fat to insulin resistance in
peripheral organs, such as skeletal muscle. We previously
demonstrated that skeletal muscle cells treated with con-
ditioned medium from adipocytes or the adipokine mono-
cyte chemotactic protein (MCP)-1 are characterized by an
impairment of insulin signaling and glucose uptake (9,10)
and could thereby deﬁne the mechanism of a negative
cross talk between adipose tissue and skeletal muscle.
Recently, the rapidly growing adipokine family was
expanded by chemerin, a secreted chemoattractant pro-
tein. Initially discovered in body ﬂuids associated with
inﬂammatory processes (11), chemerin and its receptor,
chemokine-like receptor 1 (CMKLR1, or ChemR23) are
also highly expressed in adipose tissue (12,13). In adipo-
cytes, chemerin and CMKLR1 are necessary for adipogen-
esis (13). In vivo data revealed that chemerin is elevated in
adipose tissue of diabetic Psammomys obesus compared
with control subjects (12). However, no difference in
chemerin levels between diabetic and control patients
could be observed, despite a correlation of chemerin
levels with BMI, blood triglycerides, and blood pressure
(12). Because skeletal muscle is the major postprandial
glucose-uptaking organ, the current study was meant to
describe effects of the novel adipokine chemerin on
skeletal muscle insulin sensitivity in the context of the
negative cross talk between adipose tissue and skeletal
muscle.
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BSA (fraction V, fatty acid free) was obtained from Roth (Karlsruhe, Ger-
many). Reagents for SDS-PAGE were supplied by GE Healthcare (Mu ¨nchen,
Germany) and by Sigma (Mu ¨nchen, Germany). Polyclonal antibodies anti–
phospho-glycogen synthase kinase (phospho-GSK)3/ (Ser21/9), anti–phos-
pho-Akt (Ser473), anti–phospho-nuclear factor-B (NF-B [p65, Ser536]),
anti–phospho-extracellular signal–regulated kinase (phospho-ERK)-1/2
(Thr202/Tyr204), and anti–phospho-p38 mitogen-activated protein (phospho-
p38 MAP) kinase (Thr180/Tyr182) were supplied by Cell Signaling Technology
(Frankfurt, Germany) and anti-tubulin from Calbiochem (Merck Biosciences,
Schwalbach, Germany). Chemerin, CMKLR1, actin, and adiponectin antibod-
ies were purchased from Abcam (Cambridge, U.K.) and an antibody against
myosin heavy chain (MHC) from Upstate (San Diego, CA). Horseradish
peroxidase–conjugated goat anti-rabbit and anti-mouse IgG antibodies were
from Promega (Mannheim, Germany). Collagenase NB4 standard grade was
obtained from Serva (Heidelberg, Germany) and culture media from Life
Technologies/Gibco (Berlin, Germany). Recombinant human chemerin (Esch-
erichia coli derived, molecular mass 16 kDa) was supplied by R&D Systems
(Wiesbaden-Nordenstadt, Germany). TNF- was purchased from Sigma and
adiponectin from Biovendor (Heidelberg, Germany). Primary human skeletal
muscle cells and supplement pack for growth medium were obtained from
PromoCell (Heidelberg, Germany). 2-Deoxy-D-[1-
14C] glucose was purchased
from GE Healthcare. The enzyme-linked immunosorbent assay (ELISA) kit for
phospho-insulin receptor substrate-1 (phospho-IRS-1 [Ser307]; coated anti-
body against mouse IRS-1 and detection antibody against rabbit phosphor-
IRS-1 [Ser307]) was purchased from Cell Signaling Technology. All other
chemicals were of the highest analytical grade commercially available and
were purchased from Sigma.
Culture of human skeletal muscle cells. Satellite cells were isolated from
rectus abdominis muscle by enzymatic digestion with trypsin followed by a
puriﬁcation step with ﬁbroblast-speciﬁc magnetic beads to prevent contami-
nation with ﬁbroblasts. Primary human skeletal muscle cells from three
different healthy Caucasian donors were supplied as proliferating myoblasts
(5  10
5 cells) and cultured as described in our earlier study (14). For an
individual experiment, myoblasts were seeded in six-well culture dishes at a
density of 10
5 cells per well and were cultured in -modiﬁed Eagle’s/Ham’s
F-12 medium containing skeletal muscle cell growth medium supplement pack
up to near conﬂuence. The cells were then differentiated and fused by culture
in -modiﬁed Eagle’s medium for 4 days before they were used in experi-
ments. The expression of the myogenin markers myogenin, MyoD, and MHC
reached a plateau at 4 days until at least 6 days of culture. Experiments were
repeated with the same donor but always with a different cryo-conserved
aliquot of cells. The cells were always used in the 4th passage.
Adipocyte isolation and culture. Adipose tissue samples were obtained
from the mammary fat of normal or moderately overweight women undergo-
ing surgical mammary reduction. The procedure to obtain adipose tissue was
approved by the ethical committee of Heinrich-Heine-University Duesseldorf
(Duesseldorf, Germany). All subjects were healthy, free of medication, and
had no evidence of diabetes according to routine laboratory tests. Adipose
tissue samples were dissected from other tissues and minced in pieces of 10
mg in weight. Preadipocytes were isolated by collagenase digestion as we
have previously described (14). Isolated cell pellets were resuspended in
Dulbecco’s modiﬁed Eagle’s medium (DMEM)/Ham’s F12 medium supple-
mented with 10% FCS and kept in culture for 16 h. After washing, culture was
continued in an adipocyte differentiation medium (DMEM/F12, 33 mol/l
biotin, 17 mol/l D-pantothenic acid, 66 nmol/l insulin, 1 nmol/l triiodo-L-
thyronin, 100 nmol/l cortisol, 10 g/ml apo-transferrin, 50 g/l gentamicin, 15
mmol/l HEPES, and 14 mmol/l NaHCO3, pH 7.4) supplemented with 5 mol/l
troglitazone for 3 initial days. After 15 days, 70–90% of seeded preadipocytes
developed to differentiated adipose cells, as deﬁned by cytoplasm completely
ﬁlled with small or large lipid droplets. These cells were then used for
experiments or generation of adipocyte-conditioned medium, as we have
recently described (15). Brieﬂy, after in vitro differentiation, adipocytes were
washed with skeletal muscle cell differentiation medium, and conditioned
medium was then generated by culturing adipocytes for 48 h in the same
medium followed by collection of the medium.
We used subcutaneous adipose tissue from both abdominal and mammary
areas (see subsection “Clinical studies”). There was no evidence of apparent
differences in chemerin effects using preadipocytes from the two sources.
Clinical studies of chemerin release from adipose tissue. A total of 26
obese (BMI 30 kg/m
2) otherwise healthy and 27 lean (BMI 	25 kg/m
2)
healthy women were investigated in the morning after an overnight fast. They
were investigated 1 week prior to the expected start of their menstruation
period. Their age (mean 
 SD) was 36 
 7 and 35 
 8 years, respectively. A
venous blood sample was obtained for analysis of glucose and insulin to be
used as an estimation of insulin sensitivity in vivo, using homeostasis model
assessment (HOMA) index as previously described (16). Thereafter, an
abdominal subcutaneous adipose tissue biopsy was obtained by needle
aspiration as previously described (17). One part of the tissue was used for
measurements of chemerin release as described elsewhere (18). In brief, 300
mg of tissue was incubated at 37°C for2hi na nalbumin buffer (pH 7.4), and
chemerin in the medium was determined and related to the number of fat cells
incubated or to the adipose tissue wet weight. Methodological experiments
revealed that chemerin release was linear with time for at least 3 h, suggesting
no important cell damage. Another part of the tissue was subjected to
collagenase administration, and mean adipocyte volume and weight were
determined as previously described (19). Isolated fat cells were incubated for
2 h at 37°C in an albumin concentration buffer without or with increasing
concentrations of insulin. Lipolysis or lipogenesis (incorporation of
14C
glucose into lipids) was determined as previously described (19). From the
insulin concentration response curves, the following parameters were deter-
mined as previously described (19): 1) half-maximum effective concentration,
which was transformed to a negative logarithm value (pD2); 2) lipolysis or
lipogenesis at maximum effective insulin concentration expressed either per
number of fat cells or per lipid weight of the incubated cells; and 3) basal
lipolysis or lipogenesis. The study was explained in detail to each woman, and
written informed consent was obtained. The investigation was approved by
the ethics committee at Karolinska Institutet.
Measurement of chemerin in conditioned medium and supernatant
from adipose tissue explants. Chemerin ELISA kits were purchased from
Biovendor and used according to the manufacturer. The intra- and interassay
coefﬁcients of variation for the chemerin ELISA were 6.1 and 7.6%, respectively.
Immunoblotting. Muscle cells and adipocytes were treated as indicated and
lysed in a buffer containing 50 mmol/l HEPES (pH 7.4), 1% (vol/vol) Triton-X,
PhosStop, and Complete protease inhibitor cocktail from Roche. After incubation
f o r2ha t4°C, the suspension was centrifuged at 10,000g for 15 min. Thereafter,
5 g of lysates were separated by SDS-PAGE using 10 or 15% horizontal gels and
transferred to polyvinylidene ﬂuoride ﬁlters in a semidry blotting apparatus (20).
Detection ﬁlters were blocked with Tris-buffered saline containing 0.1% Tween-20
and 5% nonfat dry milk and subsequently incubated overnight with a dilution
of appropriate antibodies in Tris-buffered saline containing 0.1% Tween-20
and 5% nonfat dry milk or 5% BSA. After washing, ﬁlters were incubated
with secondary horseradish peroxidase–coupled antibody and processed
for enhanced chemiluminescence detection using Uptilight (Interchim,
France) or Immobilon Western detection reagents (Millipore, Schwalbach,
Germany). Signals were visualized and evaluated on a LUMI Imager work
station (Boehringer Mannheim, Mannheim, Germany).
Glucose uptake in skeletal muscle cells. At 4 days after start of differen-
tiation, skeletal muscle cells were used for glucose uptake experiments.
Uptake of 2-desoxy-glucose was measured for 2 h after an acute 30-min insulin
stimulus (10
7 mol/l insulin) as described before (21).
Presentation of data and statistics. Data are the means 
 SEM. Unpaired
two-tailed Student t test or one-way ANOVA (post hoc test: Newman-Keuls
multiple comparison test) were used to determine statistical signiﬁcance. All
statistical analyses were performed using Prism (GraphPad, LA Jolla, CA)
considering a P value of 	0.05 as statistically signiﬁcant. Corresponding signiﬁ-
cance levels are indicated in the ﬁgures. Additional patient characteristics with
appropriate statistics are provided as supplementary material in the online
appendix, available at http://diabetes.diabetesjournals.org/cgi/content/full/db09-
0277/DC1.
RESULTS
Chemerin and CMKLR1 expression in primary human
adipocytes and skeletal muscle cells. In adipocytes, we
could detect chemerin protein throughout differentiation
(Fig. 1A). Chemerin levels increased with differentiation
but decreased at the end of differentiation to levels similar
to that of preadipocytes at day 0. In comparison to
chemerin, adiponectin expression was only detectable
after 3 days of differentiation and remained high until day
13 of differentiation. CMKLR1 levels also increased during
differentiation and decreased again with full differentiation
after 13 days (Fig. 1A), very similar to chemerin but
reaching the maximal expression already at day 1 of
differentiation.
Skeletal muscle cells did not express chemerin but they
did express CMKLR1 (Fig. 1B). The expression of CMKLR1
was highest in undifferentiated myoblasts and decreased
during differentiation. After 6–8 days of differentiation,
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etal muscle cells were characterized by high expression of
the myogenic marker MHC, the levels of CMKLR1 in the
myotubes was 60% lower compared with myoblasts.
Regulation of chemerin expression and secretion
from adipocytes. Chemerin expression in human adipo-
cytes was upregulated by TNF- but not inﬂuenced by
either adiponectin or troglitazone administration (Fig. 2A).
In the same cells, adiponectin was upregulated by trogli-
tazone administration, in accordance with the literature
(22,23). CMKLR1 expression was not regulated by any of
the treatments.
Human in vitro differentiated adipocytes secreted measur-
able amounts of chemerin during 48 h (Fig. 2B). The secre-
tion of chemerin increased constantly during 48 h to 15 ng/ml
from 10
6 cells. The secretion of chemerin was slightly but
signiﬁcantly upregulated by TNF- in accordance with in-
creased chemerin expression in this situation (Fig. 2A and
C). Adiponectin did not inﬂuence chemerin secretion from
adipocytes, whereas troglitazone administration led to a
marked decrease by 80% in secretion of this adipo-
kine. It can be concluded that at least in this setting,
peroxisome proliferator–activated receptor (PPAR)-
activation led to decreased chemerin release with un-
changed intracellular chemerin levels (Fig. 2A and C).
We also tested whether macrophages isolated from
human adipose tissue, using a method described by Curat
et al. (24), secrete chemerin. Chemerin could not be
detected in culture media from these macrophages and in
media from skeletal muscle cells (data not shown).
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FIG. 1. Expression of chemerin and CMKLR1 in human skeletal muscle cells and adipocytes. A: Human adipocytes from different donors were
differentiated for the indicated time, and total cell lysates were resolved by SDS-PAGE. Western blots for chemerin, adiponectin, and CMKLR1
as well as normalization for actin are shown. Data are the means  SEM of three to four independent experiments. All data were normalized to
the level of actin expression and are expressed relative to the expression level at day 0. *Signiﬁcantly different from day 0. B: Skeletal muscle
cells from different donors were differentiated for the indicated time, and total cell lysates were resolved by SDS-PAGE. Western blots for
CMKLR1 and MHC as well as normalization for tubulin are shown. Data are the means  SEM of three independent experiments. All data were
normalized to the level of tubulin expression and are expressed relative to the expression level at day 0. The right panel shows that skeletal
muscle cells from two different donors (SkM1 and SkM2) have no expression of chemerin compared with adipocytes harvested at day 0, 1, and
3 of differentiation. *Signiﬁcantly different from day 0.
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increased with obesity. Measurement of chemerin re-
lease over the course of 2 h from adipose tissue biopsies
obtained from lean and obese female subjects revealed a
signiﬁcantly higher release of chemerin in obesity (Fig. 3).
Chemerin secretion was signiﬁcantly higher when ex-
pressed as nanograms of release per gram adipose tissue
explant and also when expressed in relation to fat cell
number.
Chemerin release correlated with BMI, waist-to-hip ra-
tio, and fat cell volume (Fig. 4), whereas no correlation
could be found for clinical parameters such as insulin,
HOMA, blood lipids, and blood pressure (data not shown).
However, a signiﬁcant relationship could be found be-
tween secretion of chemerin and insulin sensitivity of
adipocyte lipogenesis and insulin-stimulated antilipolysis.
At the same time, chemerin did not correlate with basal or
maximal insulin-inhibited lipolysis or lipogenesis (data not
shown).
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FIG. 2. Regulation of chemerin and CMKLR1 expression and chemerin secretion in human adipocytes. A: Human adipocytes from different
donors were differentiated and incubated with either 2.5 nmol/l TNF-, 5 nmol/l adiponectin, or 5 mol/l troglitazone overnight. Total cell
lysates were resolved by SDS-PAGE. Western blots for chemerin, adiponectin, and CMKLR1 as well as normalization for actin are shown.
Data are the means  SEM of three to four independent experiments. All data were normalized to the level of actin expression and are
expressed relative to the unstimulated control. *Signiﬁcantly different from control. B: Human adipocytes from different donors were
differentiated, and conditioned medium was collected after different periods of incubation. The release of chemerin was analyzed using a
chemerin ELISA. Data are the means  SEM of three independent experiments. C: Human adipocytes from different donors were treated
with 2.5 nmol/l TNF-, 5 nmol/l adiponectin, or 5 mol/l troglitazone overnight, and the conditioned medium was collected for chemerin
measurement. Data are the means  SEM of three independent experiments. All data are expressed relative to the unstimulated control.
*Signiﬁcantly different from control.
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FIG. 3. Secretion of chemerin from adipose tissue explants derived
from lean and obese female subjects. Adipose tissue explants were
treated as detailed in the RESEARCH DESIGN AND METHODS section, and the
release of chemerin was measured by ELISA. Data are the means 
SEM of tissue explants from 53 individuals. *Signiﬁcantly different
from lean control subjects.
CHEMERIN AND MUSCLE INSULIN RESISTANCE
2734 DIABETES, VOL. 58, DECEMBER 2009 diabetes.diabetesjournals.orgChemerin impaired insulin signaling and glucose up-
take in skeletal muscle cells. After overnight incubation
with chemerin, skeletal muscle cells showed a marked
decrease in insulin-stimulated Akt phosphorylation at
Ser473, GSK3 phosphorylation at Ser21, and GSK3
phosphorylation at Ser9 (Fig. 5A and B). This effect was
dose dependent because administration with 250 ng/ml of
chemerin showed a trend toward induction of insulin
resistance, whereas 1 g/ml of chemerin provoked a
signiﬁcant decrease in insulin-stimulated phosphorylation
of Akt and GSK3/. Expression of Akt and GSK3/
remained unchanged by administration of chemerin (data
not shown). Upstream of Akt, chemerin increased basal
serine phosphorylation of IRS-1 and further increased
insulin-stimulated phosphorylation of this substrate (Fig.
5C). This IRS-1 serine site is targeted by several kinases
and is known to negatively modulate insulin action.
To test whether the observed effect on insulin signaling
also translates into changes of glucose homeostasis in the
skeletal muscle cell, we measured glucose uptake. Admin-
istration of chemerin signiﬁcantly decreased insulin-stim-
ulated glucose uptake with a slight but not signiﬁcant
parallel impairment of basal glucose uptake (Fig. 5D).
Overall, the insulin-stimulated increase of glucose uptake
over the respective basal level was signiﬁcantly lower in
skeletal muscle cells treated with chemerin (910 
 110 vs.
620 
 80 cpm/3.5  10
5 cells, respectively; n  3).
Chemerin levels were lower in conditioned medium
than the concentrations used to stimulate skeletal muscle
cells. Therefore, we also used a combination of condi-
tioned medium containing different adipokines besides
chemerin and added chemerin in high concentrations to
analyze whether higher chemerin levels can add to the
effect of conditioned medium to induce insulin resistance,
as described in earlier work (10,15). Conditioned medium
and chemerin induced insulin resistance to a similar
degree, whereas addition of chemerin to conditioned
medium further decreased insulin-stimulated Akt phos-
phorylation (Fig. 6). This additive effect of conditioned
medium containing low chemerin concentrations and
added chemerin in a high concentration might indicate the
stimulation of different pathways by adipokines present in
conditioned medium and chemerin.
Chemerin activated the NF-B pathway and MAP
kinases in skeletal muscle cells. Different pathways
were analyzed to identify mechanisms that might mediate
the effect of chemerin. Chemerin rapidly activated p38
MAP kinase and ERK-1/2 in a dose-dependent manner
(Fig. 7A and B). The activation of these kinases reached its
maximum after 30 min, and the phosphorylation of both
kinases slowly decreased. The NF-B pathway was acti-
vated in a more prolonged fashion, reaching a maximal
activation of p65 by chemerin after 60 min. After 24 h of
chemerin administration, there was no signiﬁcant increase
in p38 MAP kinase phosphorylation but still signiﬁcant
activation of ERK and p65 (Fig. 7C). The expression of p38
MAP kinase, ERK-1/2, and p65 remained unchanged by
administration with chemerin (data not shown).
ERK inhibition partially restored insulin sensitivity
in chemerin-treated skeletal muscle cells. To analyze
the role of ERK in the impairment of insulin signaling by
chemerin, we preincubated skeletal muscle cells with the
speciﬁc ERK inhibitor PD 98059. In short-term experi-
ments (Fig. 8A), preincubation with the ERK inhibitor
completely blocked ERK activation by TNF- and
chemerin. After overnight incubation, the ERK inhibitor
had no effect on insulin signaling itself but could partially
prevent the impairment of insulin signaling by chemerin
(Fig. 8B). Similarly, inhibition of ERK could prevent a
chemerin-induced decrease in glucose uptake (Fig. 8C).
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FIG. 4. Correlation of chemerin release from adipose tissue explants with different parameters. A: Adipose tissue explants were treated as
detailed in the RESEARCH DESIGN AND METHODS section, and the release of chemerin was measured by ELISA. Chemerin release was correlated with
BMI, waist-to-hip ratio, and adipocyte volume. B: Lipogenesis and insulin-stimulated antilipolysis was measured as described in the RESEARCH
DESIGN AND METHODS section. Values for antilipolysis are not normally distributed, but the correlation remains signiﬁcant, using a nonparametric
test (Spearman rank test).
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speciﬁc effect of chemerin on insulin signaling in skeletal
muscle cells but that other pathways could also be in-
volved in this process because ERK inhibition is not able
to completely reverse chemerin-induced reduction in in-
sulin-stimulated Akt phosphorylation.
DISCUSSION
Adipokines such as TNF- and interleukin (IL)-6 are
signiﬁcantly increased in obesity and are good predictors
for the development of type 2 diabetes (25,26). TNF-,
IL-6, and MCP-1 have been identiﬁed to contribute in vitro
to insulin resistance (27,28) and might be regulators of
insulin sensitivity. Increased concentrations of the chemo-
kines MCP-1, IL-8, and IP-10 (interferon-–inducible pro-
tein-10) have been described to be associated with
incident type 2 diabetes (29,30). Their role as important
immune mediators in physiological and pathological pro-
cesses might also translate into increased macrophage
inﬁltration into adipose tissue as it has been observed in
obesity (31–33). Therefore, chemoattractant proteins rep-
resent an ideal link between obesity-associated changes in
adipose tissue and an increased risk for metabolic dis-
eases such as type 2 diabetes.
Chemerin is a novel chemokine and adipokine with a
described role in host survival defense, including comple-
ment ﬁbronolysis and coagulation. Although ﬁrst de-
scribed as a chemokine occurring in ﬂuids during
inﬂammatory processes such as cancer and rheumatoid
arthritis (11), chemerin is also expressed in adipose tissue.
We can demonstrate that in vitro differentiated adipocytes
release measurable amounts of chemerin and express
CMKLR1. Several studies describe similarly that chemerin
mRNA expression increases with adipogenesis in 3T3 L1
adipocytes, but two of the studies comprise completely
divergent data on the regulation of CMKLR1 (12,13,34). In
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FIG. 5. Effect of chemerin on insulin signaling and glucose uptake in human skeletal muscle cells. A: Myocytes from different donors were cultured
with increasing concentrations of chemerin (250 ng/ml and 1 g/ml) for 24 h. After acute stimulation with insulin, total cell lysates were resolved
by SDS-PAGE and immunoblotted with phosphospeciﬁc Akt antibody and tubulin antibody. Data are the means  SEM of ﬁve independent
experiments. All data were normalized to the level of tubulin expression and are expressed relative to the insulin-stimulated control value. B:
Myocytes from different donors were cultured as outlined in A. After acute stimulation with insulin, total cell lysates were resolved by SDS-PAGE
and immunoblotted with phosphospeciﬁc GSK3 antibody and GSK3 antibody. Data are the means  SEM of four independent experiments. All
data were normalized to the level of tubulin expression and are expressed relative to the insulin-stimulated control value. C and D: Skeletal
muscle cells were cultured for 24 h in absence or presence of chemerin (1 g/ml). IRS-1 phosphorylation and glucose uptake was assessed after
acute stimulation with insulin, as outlined in the RESEARCH DESIGN AND METHODS section. Data are the means  SEM of three independent
experiments. *Signiﬁcantly different from insulin-stimulated control; §signiﬁcantly different from respective insulin-stimulated control. f,
insulin; , basal.
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sion increase with differentiation (13), the effect being
more pronounced for CMKLR1. We can also ﬁnd increased
expression of chemerin and CMKLR1 at the protein level
during differentiation that does not, however, last until the
end of differentiation. The use of freshly isolated subcuta-
neous adipocytes and a distinct differentiation protocol
might explain this difference. In adipose tissue, chemerin
can also be found in the stroma-vascular fraction, pointing
to a contribution of different adipose tissue cell types to
chemerin production. Unable to detect chemerin release
from macrophages isolated from adipose tissue, we can
demonstrate that this cell type, which is so critical for
adipose tissue inﬂammation, does not contribute to
chemerin release. However, it has been described that
macrophages express CMKLR1 and are chemerin respon-
sive (35). Chemerin is expressed similarly in human prea-
dipocytes and adipocytes, making it possible that
adipocytes and preadipocytes are the main cells secreting
this adipokine within adipose tissue.
The current knowledge of chemerin is more compli-
cated, including more targets than chemerin and CMKLR1.
Chemerin is synthesized as prochemerin with low afﬁnity
to CMKLR1 (11). Prochemerin is rapidly converted into
chemerin by proteolytic cleavage of a COOH-terminal
peptide, involving serine proteases of the coagulation and
inﬂammation cascades (11). COOH-terminal peptides de-
rived from chemerin by cysteine protease cleavage bind to
CMKLR1 with much higher afﬁnity than chemerin itself
and exert potent anti-inﬂammatory effects on activated
macrophages (36,37). This divergent effect of chemerin
and chemerin-derived peptides can be explained by their
binding to other receptors recently identiﬁed, such as
GPR1 (G-protein–coupled receptor 1) and orphan serpen-
tine receptor chemokine (CC motif) receptor-like 2
(CCRL2) (37,38). In detail, chemerin binds with its COOH
terminus to CMKLR1, directly activating cells, but
chemerin can also bind CCRL2 on its NH2-terminal domain
and present the COOH terminus to CMKLR1 on neighbor-
ing cells. Differently, chemerin-derived peptides can only
bind to CMKLR1 and inhibit an inﬂammatory response, a
process that is similarly known for other chemokines,
such as MCP-1 or RANTES (regulated on activation,
normal T expressed and secreted) (39,40). In this study,
we observed a proinﬂammatory action of chemerin on
skeletal muscle cells. The role of the novel chemerin
receptors and chemerin-derived peptides in the context of
obesity and type 2 diabetes is not known. Further work is
also necessary to assess the effects of chemerin-derived
peptides in this respect.
Chemerin expression is not increased in adipose tissue
of genetically obese mice (13) or even lower in db/db mice
(41), but it is higher in obese, insulin-resistant P. obesus
(12). The initial study on chemerin in humans revealed a
correlation of chemerin blood levels with BMI, indepen-
dent of glucose tolerance (12). Very recent publications
could also demonstrate an association of chemerin with
markers of the metabolic syndrome and inﬂammation
(42–44). We can show that the release of chemerin is
clearly increased from adipose tissue explants of obese
patients compared with lean control subjects. Further-
more, chemerin release from adipose tissue correlated
with waist-to-hip ratio and fat cell volume, whereas no
correlation could be found with blood pressure and
HOMA. Interestingly, chemerin secretion was negatively
correlated with insulin sensitivity of the adipocytes be-
cause higher chemerin release was associated with lower
insulin sensitivity of lipogenesis and lower insulin-stimu-
lated antilipolysis. In conclusion, we could show that
chemerin was released by human adipose tissue, and in
obesity its amounts were increased. Chemerin correlated
with insulin sensitivity of the fat cell, potentially leading to
local insulin resistance in obesity. Thus, chemerin might,
clinically, serve as a marker for body composition. Its
possible role as marker for metabolic control and ho-
meostasis needs to be explored further.
We demonstrated in this study that chemerin secretion
by adipocytes is regulated in vitro and that the release of
chemerin from adipose tissue explants correlates with
various features of the metabolic syndrome. It would be
interesting to also study the in vivo effect of chemerin.
This is unfortunately not possible because chemerin is not
registered for therapeutic use in humans. Chemerin is
secreted at concentrations of 15 ng/ml from 10
6 cells,
which is relatively low compared with the concentrations
used on skeletal muscle cells of 250 ng/ml to 1 g/ml. The
latter reﬂect serum concentrations of this chemokine in
lean (249 
 71 ng/ml measured in 142 patients) (12) and
obese patients (measured chemerin levels in 4 morbidly
obese women of 674 
 37 ng/ml, BMI 48–55 kg/m
2,
unpublished data). The contribution of liver, lung, and
other chemerin-producing organs to chemerin blood levels
have to be taken into account.
In accordance with chemerin secretion being elevated
from adipose tissue of obese patients and published data
on chemerin showing it to be related to obesity (12), the
expression and secretion of this chemokine by adipocytes
was upregulated by TNF-. Interestingly, the PPAR-
agonist troglitazone strongly suppressed the release of
chemerin while having no effect on its expression. This
observation might add to the wide area of action of these
compounds (45). A very recent publication revealed that
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diabetes.diabetesjournals.org DIABETES, VOL. 58, DECEMBER 2009 2737chemerin secretion is increased by insulin in adipose
tissue explants, whereas metformin is able to reduce
chemerin secretion (46). Metformin also reduces chemerin
blood levels without decreasing BMI in women with
polycystic ovary syndrome.
A role for chemerin was not only described in chemoat-
traction and macrophage inﬁltration into adipose tissue,
but also in adipogenesis and adipocyte metabolism
(13,34,41). Chemerin is necessary for normal adipogenesis,
but, as we show here, also induces insulin resistance in
peripheral tissues such as skeletal muscle. We observed a
clear inhibitory effect of chemerin on skeletal muscle cell
glucose uptake, but in 3T3 adipocytes chemerin has the
opposite effect (41), namely increasing insulin-stimulated
glucose uptake. Thus, chemerin may exert different action
in endocrine and paracrine/autocrine ways. Other che-
mokines such as MCP-1 are also known to induce
insulin resistance in skeletal muscle cells also involving
activation of ERK-1/2 similarly to chemerin (9). How-
ever, there are differences in their mode of action
because MCP-1 does not activate the NF-B pathway,
whereas chemerin does.
In summary, our data show that skeletal muscle is a
target tissue for chemerin, which might be involved in the
negative cross talk between skeletal muscle and adipose
tissue. The possible role of chemerin as a link between
obesity and diabetes needs, however, to be established by
further studies because cell types other than adipocytes
secrete this cytokine and may contribute to its effect on
skeletal muscle cells. Other adipokines already tested for
their ability to disturb insulin-stimulated glucose ho-
meostasis in skeletal muscle are also involved in inﬂam-
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FIG. 7. Chemerin signaling in skeletal muscle cells. A: Skeletal muscle cells from different donors were cultured with chemerin for 30 min
and as a control with 2.5 nmol/l TNF- for 10 min. Total cell lysates were resolved by SDS-PAGE and immunoblotted with phosphospeciﬁc
antibodies for p38 MAP kinase, the p65 subunit of NF-B (p65), and ERK-1/2 and tubulin for loading control. Representative blots are
shown. B: Skeletal muscle cells from different donors were cultured with chemerin for 10–120 min. Total cell lysates were resolved by
SDS-PAGE and immunoblotted with phosphospeciﬁc antibodies for p38 MAP kinase, the p65 subunit of NF-B (p65), and ERK-1/2 and
tubulin for loading control. Data are the means  SEM of four to ﬁve independent experiments. *Signiﬁcantly different from unstimulated
control. C: Skeletal muscle cells from different donors were cultured with different concentrations of chemerin for 24 h. Total cell lysates
were resolved by SDS-PAGE and immunoblotted with phosphospeciﬁc antibodies for p38 MAP kinase, the p65 subunit of NF-B (p65), and
ERK-1/2 and tubulin for loading control. Data are the means  SEM of four to ﬁve independent experiments. *Signiﬁcantly different from
unstimulated control.
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2738 DIABETES, VOL. 58, DECEMBER 2009 diabetes.diabetesjournals.orgmation, and it must be emphasized that there is most likely
not a single adipokine that is fully responsible for obesity-
associated metabolic complications, including insulin re-
sistance in skeletal muscle. It is apparent that the role of
adipokines in obesity and its associate metabolic compli-
cations is complex, involving numerous proteins that may
act independently or in consonance. A rather complicated
interplay between a huge number of adipokines and their
overlapping physiological effects adds to other environ-
mental or genetic factors to decide the development of
type 2 diabetes.
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